Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.
Aptadir Therapeutics has raised $1.6M in total funding. The most recent round was Pre-Seed. The last funding was announced in September 2024.
Aptadir Therapeutics's investors include CDP Venture Capital, Evotec, Angelini Ventures.
Aptadir Therapeutics is headquartered in Milan, Italy.
Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.
Aptadir Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aptadir Therapeutics — Funding & Investors." VCBacked, September 24, 2024, https://www.vcbacked.co/company/aptadir-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Aptadir Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/aptadir-therapeutics
{{cite web |title=Aptadir Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aptadir-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated